Tag Archives: biotechnology law

Myriad Ruling: DNA Sequences Are Unpatentable “ Products Of Nature”

Posted on March 30, 2010 by Warren Woessner

In a lengthy opinion released yesterday in Assoc. for Molec. Pathology v. USPTO, __F.Supp.2d___(S.D. N.Y.) (PDF below), the court invalidated claims directed to isolated DNA sequences, as well as to cancer screening methods using them, and even to methods of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | 1 Comment

Centocor v. Abbott Labs. – “Antibody Exception” To Written Description Requirement Under Fire

Posted on March 29, 2010 by Warren Woessner

Abbott Laboratories markets a recombinant human antibody, HUMIRA, as a treatment for rheumatoid arthritis. This antibody binds to a receptor on TNF. NYU and Centocor own US Pat No 7070775 which claims an isolated recombinant anti-TNF-a antibody (Ab) comprising a … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | Leave a comment

Regulatory Framework For Follow-On Biologics In Health Care Bill

Posted on March 26, 2010 by Warren Woessner

In the early evening of March 25, 2010, the House voted, finalizing the budget reconciliation package earlier passed by the Senate, that contained some relatively minor amendments to the version of the Senate Bill that the House passed in the … Continue reading →

Posted in Follow-On Biologics | Tagged , , , , , , , | 3 Comments

Ariad v. Lilly Comes Down (On Us) – Judge Lourie Rules!

Posted on March 23, 2010 by Warren Woessner

In a majority opinion authored by Judge Lourie for the Federal Circuit sitting en banc (Appeal No. 2008-1248 (Fed. Cir. March 22, 2010)) (a PDF of which is attached to the end of this post), the court held that there … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , | 1 Comment